A study for observing severe asthma in patients treated with tezepelumab

Trial Identifier:	D5180R00011
Sponsor:	AstraZeneca
NCTID::	NCT05677139
Start Date:	December 2022
Primary Completion Date:	December 2024
Study Completion Date:	December 2024
Condition:	Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Canada, Ontario	Toronto, Ontario, Canada, M5G 1E2

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.